Focused on select Small Cap London equities, our #AIM is to keep investors informed. →Comprehensive PLC Reports →Market News Analysis →Independent →Authorative
Destiny Pharma - A Biotech Company for the Age of Infectious Diseases
Read analysis of #LSE listed PLC and progress of its XF-73 clinical trials here
$DEST $DEST.L
#DEST#AIM#XF73#AMR
https://t.co/5fcq4v021r
#DEST investors will find this #Radio4 podcast of interest: Discourse on pressing threat of #AMR & actions being taken to address it
Panelists include Pfizer Exec, Goldman-Sachs Chief Economist & Founder of Antibiotic Research UK
First aired in June 2019
https://t.co/QKCWDGZKiF
Simpvestor delves into details of an upbeat trading update from Digital Learning specialist @LTGplc
In our latest article we discuss acquisitions, Moodle, a Royal Navy contract & look at what 2021 has in store
$LTG.L
$LTG
#LTG#LSE
Article linked here:
https://t.co/oLAyAQRA0F
#DEST
Very good overview of Destiny Pharma pipeline timelines & a must read for investors looking for Biotech opportunities
https://t.co/U4fgpLNdoO
#DEST Awaiting Phase 2b clinical trial results for its flagship XF73 product, Destiny Pharma is fast approaching an inflection point
We take a look at what is at stake for the company and its shareholders
$DEST $DEST.L
#FTSE#LSE#UKPharma#BioTech
https://t.co/VPtBh8CKQg
#ANGS receives OGA all clear for Lidsey production.
Good job BoD for sticking to guns & delivering on targets.
#WealdBasin#simpvestor https://t.co/aUvWppAGlU
Seems good time to add #copper.
#CAML looks good way to do so.
$CAML, all you need to know in our PLC report on:
https://t.co/xcBLg8q6ou https://t.co/cZQTqx2hvv
Bad news for #Vernalis today.
2nd #FDA rejection: CCP-08. Poor comms from BoD, what aren't they revealing? ⚠️Danger⚠️
$VER.L #TrisPharma https://t.co/0Lj6KuaADB